Irritable bowel syndrome

Warning: Undefined array key "S1" in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Irritable bowel syndrome.php on line 2
Irritable bowel syndrome

LE WE PMID CA

Irritable bowel syndrome

2389

Reizdarm

Alosetron

Amygdala

Asimadoline ttOpiatK

Cajal Interstitial cells of Cajal

Celiac disease

Chromogranin A

Constipation

Gabapentin

Gastroesophageal reflux disease

Inflammatory bowel diseases

Irritable bowel syndrome

Linaclotide ttGuanylatecyclaseC

Lubiprostone

Mast cells

Microbiomics

Otilonium bromide

Pregabalin

SeHCAT

Stress (Neurophysiology)

Tegaserod

TRPV1

Tryptophan hydroxylase

2001 1	Pathophysiology and management of irritable bowel syndrome. [11769571] Korean J Intern Med 16(3): 137-46 (2001)
2003 2	A systematic review of alternative therapies in the irritable bowel syndrome. [12578506] Arch Intern Med 163(3): 265-74 (2003)
2001 3	Evidence- and consensus-based practice guidelines for the diagnosis of irritable bowel syndrome. [11570936] Arch Intern Med 161(17): 2081-8 (2001)
2009 4	Complementary and alternative medicine for treatment of irritable bowel syndrome. [19221071] Can Fam Physician 55(2): 143-8 (2009)
1994 5	Irritable bowel syndrome. Strategy for the family physician. [8130678] Can Fam Physician 40(-): 307-10, 313-6 (1994)
2005 6	Cognitive-behavioral treatment of irritable bowel syndrome. [16273018] CNS Spectr 10(11): 883-90 (2005)
2004 7	Treating irritable bowel syndrome: overview, perspective and future therapies. [15037521] Br J Pharmacol 141(8): 1237-48 (2004)
2007 8	Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom. [18360619] Ther Clin Risk Manag 3(1): 107-18 (2007)
2009 9	Autonomic testing in functional gastrointestinal disorders: implications of reproducible gastrointestinal complaints during tilt table testing. [19424509] Gastroenterol Res Pract 2009(-): 868496 (2009)
2008 10	Review article: abdominal bloating and distension in functional gastrointestinal disorders--epidemiology and exploration of possible mechanisms. [17931344] Aliment Pharmacol Ther 27(1): 2-10 (2008)
2007 11	Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. [17661757] Aliment Pharmacol Ther 26(4): 535-44 (2007)
2007 12	Systematic review: the prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. [17593064] Aliment Pharmacol Ther 26(2): 183-93 (2007)
2007 13	Review article: the role of antibiotics vs. conventional pharmacotherapy in treating symptoms of irritable bowel syndrome. [17509095] Aliment Pharmacol Ther 25(11): 1271-81 (2007)
2006 14	Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. [16948804] Aliment Pharmacol Ther 24(6): 919-33 (2006)
2006 15	Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome. [16918880] Aliment Pharmacol Ther 24(5): 769-80 (2006)
2006 16	Systematic review: the safety and tolerability of pharmacological agents for treatment of irritable bowel syndrome--a European perspective. [16842449] Aliment Pharmacol Ther 24(2): 207-36 (2006)
2006 17	Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. [16842448] Aliment Pharmacol Ther 24(2): 183-205 (2006)
2006 18	Review article: intestinal serotonin signalling in irritable bowel syndrome. [16611266] Aliment Pharmacol Ther 23(8): 1067-76 (2006)
2006 19	Systematic review: Complementary and alternative medicine in the irritable bowel syndrome. [16441466] Aliment Pharmacol Ther 23(4): 465-71 (2006)
2005 20	Review article: The history of hypnotherapy and its role in the irritable bowel syndrome. [16305719] Aliment Pharmacol Ther 22(11-12): 1061-7 (2005)
2005 21	Review article: drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders--the clinical evidence. [15771750] Aliment Pharmacol Ther 21(6): 633-51 (2005)
2004 22	Meta-analysis: The treatment of irritable bowel syndrome. [15606387] Aliment Pharmacol Ther 20(11-12): 1253-69 (2004)
2004 23	Review article: therapeutic roles of acupuncture in functional gastrointestinal disorders. [15479354] Aliment Pharmacol Ther 20(8): 831-41 (2004)
2004 24	Irritable bowel syndrome - an evidence-based approach to diagnosis. [15191504] Aliment Pharmacol Ther 19(12): 1235-45 (2004)
2004 25	Review article: The rationale for antidepressant therapy in functional gastrointestinal disorders. [15113363] Aliment Pharmacol Ther 19(9): 969-79 (2004)
2004 26	Systemic review: Natural history of irritable bowel syndrome. [15080847] Aliment Pharmacol Ther 19(8): 861-70 (2004)
2004 27	Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. [14984370] Aliment Pharmacol Ther 19(3): 245-51 (2004)
2003 28	Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome. [12969083] Aliment Pharmacol Ther 18(6): 569-80 (2003)
2003 29	Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. [12848622] Aliment Pharmacol Ther 18(1): 1-16 (2003)
2003 30	Systematic review: Abdominal and pelvic surgery in patients with irritable bowel syndrome. [12694081] Aliment Pharmacol Ther 17(8): 997-1005 (2003)
2003 31	Review article: visceral hypersensitivity. [12641510] Aliment Pharmacol Ther 17(5): 623-33 (2003)
2002 32	Review article: bloating in functional bowel disorders. [12390095] Aliment Pharmacol Ther 16(11): 1867-76 (2002)
2002 33	Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. [12182741] Aliment Pharmacol Ther 16(8): 1407-30 (2002)
2002 34	The treatment of irritable bowel syndrome. [12182740] Aliment Pharmacol Ther 16(8): 1395-406 (2002)
2002 35	Review article: the complexity of drug development for irritable bowel syndrome. [11876686] Aliment Pharmacol Ther 16(3): 343-51 (2002)
2001 36	Food hypersensitivity and irritable bowel syndrome. [11284772] Aliment Pharmacol Ther 15(4): 439-49 (2001)
2001 37	Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. [11207510] Aliment Pharmacol Ther 15(3): 355-61 (2001)
1998 38	Review article: colonic sensorimotor physiology in health, and its alteration in constipation and diarrhoeal disorders. [9690718] Aliment Pharmacol Ther 12(4): 287-302 (1998)
2010 39	Review article: new receptor targets for medical therapy in irritable bowel syndrome. [19785622] Aliment Pharmacol Ther 31(1): 35-46 (2010)
2009 40	Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. [19570102] Aliment Pharmacol Ther 30(7): 707-17 (2009)
2009 41	Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents. [19493256] Aliment Pharmacol Ther 30(5): 423-35 (2009)
2008 42	Review article: probiotics and prebiotics in irritable bowel syndrome. [18532993] Aliment Pharmacol Ther 28(4): 385-96 (2008)
2008 43	Review article: molecular, pathological and therapeutic features of human enteric neuropathies. [18410560] Aliment Pharmacol Ther 28(1): 25-42 (2008)
2008 44	Review article: gastrointestinal sensory and motor disturbances in inflammatory bowel disease - clinical relevance and pathophysiological mechanisms. [18221407] Aliment Pharmacol Ther 27(8): 621-37 (2008)
2004 45	Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility. [15521849] Aliment Pharmacol Ther 20 Suppl 7(-): 3-14 (2004)
2004 46	Diagnosis and therapy of irritable bowel syndrome. [15335409] Aliment Pharmacol Ther 20 Suppl 2(-): 10-22 (2004)
2004 47	New pathophysiological mechanisms in irritable bowel syndrome. [15335408] Aliment Pharmacol Ther 20 Suppl 2(-): 1-9 (2004)
1997 48	Review article: irritable bowel syndrome. [9042970] Aliment Pharmacol Ther 11(1): 3-15 (1997)
2007 49	In the clinic. Irritable bowel syndrome. [17606954] Ann Intern Med 147(1): ITC7-1-ITC7-16 (2007)
2006 50	Treatment for bacterial overgrowth in the irritable bowel syndrome. [17043344] Ann Intern Med 145(8): 626-8 (2006)
2005 51	Use of psychopharmacological agents for functional gastrointestinal disorders. [16099800] Gut 54(9): 1332-41 (2005)
2000 52	British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. [11053260] Gut 47 Suppl 2(-): ii1-19 (2000)
1984 53	The irritable bowel. [6365700] Gut 25(3): 305-20 (1984)
2003 54	Management of irritable bowel syndrome. [12697915] Postgrad Med J 79(929): 154-8 (2003)
1997 55	The irritable bowel syndrome. [9039402] Postgrad Med J 73(855): 1-7 (1997)
1991 56	Current views on the aetiology and management of the irritable bowel syndrome. [1946124] Postgrad Med J 67(791): 785-9 (1991)
2008 57	Meta-analysis of probiotics for the treatment of irritable bowel syndrome. [18461650] World J Gastroenterol 14(17): 2650-61 (2008)
2008 58	Updates on treatment of irritable bowel syndrome. [18461649] World J Gastroenterol 14(17): 2639-49 (2008)
2007 59	Neuropathophysiology of functional gastrointestinal disorders. [17457962] World J Gastroenterol 13(9): 1313-32 (2007)
2007 60	Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests? [17226899] World J Gastroenterol 13(2): 219-23 (2007)
2011 61	Management of irritable bowel syndrome (IBS) in adults: conventional and complementary/alternative approaches. [21649455] Altern Med Rev 16(2): 134-51 (2011)
2004 62	The causes of intestinal dysbiosis: a review. [15253677] Altern Med Rev 9(2): 180-97 (2004)
2006 63	How stress induces intestinal hypersensitivity. [16400003] Am J Pathol 168(1): 3-5 (2006)
2008 64	Diagnosis and management of irritable bowel syndrome in adults in primary care: summary of NICE guidance. [18325967] BMJ 336(7643): 556-8 (2008)
2006 65	Functional findings in irritable bowel syndrome. [16718806] World J Gastroenterol 12(18): 2830-8 (2006)
2011 66	Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. [21734786] World J Gastroenterol 17(23): 2791-800 (2011)
2008 67	Postinfectious irritable bowel syndrome. [18205536] Clin Infect Dis 46(4): 594-9 (2008)
2004 68	Role of serotonin in the pathophysiology of the irritable bowel syndrome. [15100164] Br J Pharmacol 141(8): 1285-93 (2004)
2011 69	Interstitial cells of Cajal: a novel hypothesis for the pathophysiology of irritable bowel syndrome. [21647464] Can J Gastroenterol 25(5): 277-9 (2011)
2011 70	Neuroimmune mechanisms in functional bowel disorders. [21411840] Neth J Med 69(2): 55-61 (2011)
2006 71	Histopathological alterations in irritable bowel syndrome. [17013373] Mod Pathol 19(12): 1638-45 (2006)
2010 72	Gastro-esophageal reflux disease and irritable bowel syndrome - why are they associated? [20486743] Rev Esp Enferm Dig 102(4): 225-8 (2010)
2005 73	Provocation tests in functional gastrointestinal diseases: mechanistic diagnosis and therapeutic intervention. [15982176] Rev Esp Enferm Dig 97(4): 219-22 (2005)
2011 74	Gastrointestinal motility disorders in endocrine diseases. [21532535] Pol Arch Med Wewn 121(4): 129-36 (2011)
2009 75	The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome. [19337629] J Gastrointestin Liver Dis 18(1): 23-6 (2009)
2011 76	Corticosterone mediates reciprocal changes in CB 1 and TRPV1 receptors in primary sensory neurons in the chronically stressed rat. [21070780] Gastroenterology 140(2): 627-637.e4 (2011)
2008 77	Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. [18252749] Gut 57(7): 923-9 (2008)
2003 78	Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. [12573376] Lancet 361(9355): 385-91 (2003)
2007 79	Guidelines on the irritable bowel syndrome: mechanisms and practical management. [17488783] Gut 56(12): 1770-98 (2007)
2010 80	Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome. [21180598] Therap Adv Gastroenterol 3(3): 165-72 (2010)
2009 81	The treatment of irritable bowel syndrome. [21180545] Therap Adv Gastroenterol 2(4): 221-38 (2009)
2009 82	Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. [19364994] Arch Intern Med 169(7): 651-8 (2009)
2007 83	Recurrent abdominal pain and irritable bowel syndrome in children. [17885479] Curr Opin Pediatr 19(5): 581-5 (2007)
2011 84	Alpha 2 Delta (α(2)δ) Ligands, Gabapentin and Pregabalin: What is the Evidence for Potential Use of These Ligands in Irritable Bowel Syndrome. [21713059] Front Pharmacol 2(-): 28 (2011)
2010 85	Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. [21151683] Int J Womens Health 2(-): 361-74 (2010)
2011 86	The role of experimental models in developing new treatments for irritable bowel syndrome. [21309671] Expert Rev Gastroenterol Hepatol 5(1): 43-57 (2011)
2008 87	Atopic irritable bowel syndrome: same old hat or a new entity? [19072394] Expert Rev Gastroenterol Hepatol 2(4): 457-9 (2008)
2010 88	Irritable bowel syndrome: diagnostic approaches in clinical practice. [21694856] Clin Exp Gastroenterol 3(-): 127-37 (2010)
2009 89	Current and novel therapeutic options for irritable bowel syndrome management. [19665953] Dig Liver Dis 41(12): 854-62 (2009)
2010 90	Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation. [20410554] Can J Clin Pharmacol 17(1): e194-200 (2010)
2008 91	Pediatric functional gastrointestinal disorders. [18595859] Nutr Clin Pract 23(3): 268-74 (2008)
2009 92	Genetics and irritable bowel syndrome: from genomics to intermediate phenotype and pharmacogenetics. [19655247] Dig Dis Sci 54(11): 2318-24 (2009)
2009 93	Widespread hyperalgesia in irritable bowel syndrome is dynamically maintained by tonic visceral impulse input and placebo/nocebo factors: evidence from human psychophysics, animal models, and neuroimaging. [19375508] Neuroimage 47(3): 995-1001 (2009)
2005 94	The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. [16273017] CNS Spectr 10(11): 891-6 (2005)
2009 95	Role of anxiety in the pathophysiology of irritable bowel syndrome: importance of the amygdala. [20582274] Front Neurosci 3(-): 47 (2009)
2008 96	Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. [18715494] Neurogastroenterol Motil 20(9): 971-9 (2008)
2010 97	Approaching patients with irritable bowel syndrome. [20948834] F1000 Med Rep 2(-): - (2010)
2011 98	Irritable bowel syndrome - An inflammatory disease involving mast cells. [22053295] Asia Pac Allergy 1(1): 36-42 (2011)
2011 99	LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin. [21159063] Neurogastroenterol Motil 23(3): 193-200 (2011)
PMC 100	Is irritable bowel syndrome an organic disorder? [24574708] World J Gastroenterol 20(2):384-400 (2014)
PMC 101	Molecular basis of the irritable bowel syndrome. [24574707] World J Gastroenterol 20(2):376-83 (2014)
PMC 102	Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. [24574706] World J Gastroenterol 20(2):363-75 (2014)
PMC 103	Complementary and alternative medicines in irritable bowel syndrome: an integrative view. [24574705] World J Gastroenterol 20(2):346-62 (2014)
PMC 104	Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments. [24627587] World J Gastroenterol 20(10):2499-514 (2014)
PMC 105	Melatonin for the treatment of irritable bowel syndrome. [24627586] World J Gastroenterol 20(10):2492-8 (2014)
PMC 106	Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype. [24627585] World J Gastroenterol 20(10):2482-91 (2014)
PMC 107	Unraveling the ties between irritable bowel syndrome and intestinal microbiota. [24627584] World J Gastroenterol 20(10):2470-81 (2014)
PMC 108	Irritable bowel syndrome: emerging paradigm in pathophysiology. [24627583] World J Gastroenterol 20(10):2456-69 (2014)
PMC 109	Overgrowth of the indigenous gut microbiome and irritable bowel syndrome. [24627582] World J Gastroenterol 20(10):2449-55 (2014)
PMC 110	Sex hormones in the modulation of irritable bowel syndrome. [24627581] World J Gastroenterol 20(10):2433-48 (2014)
PMC 111	Linaclotide: A Novel Therapy for Chronic Constipation and Constipation-Predominant Irritable Bowel Syndrome. [24683372] Gastroenterol Hepatol (N Y) 8(10):653-60 (2012)
PMC 112	Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review. [24741324] Clin Exp Gastroenterol 7():75-82 (2014)
PMC 113	New treatment option for irritable bowel syndrome with constipation and chronic idiopathic constipation. [24693271] Gastroenterol Hepatol (N Y) 8(12):825-8 (2012)
PMC 114	Role of gut pathogens in development of irritable bowel syndrome. [24604037] Indian J Med Res 139(1):11-8 (2014)
PMC 115	Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. [22339879] Neurogastroenterol Motil 24(6):521-30, e248 (2012)
PMC 116	Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. [24744587] World J Gastroenterol 20(14):3976-85 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Fatal error: Uncaught Error: Call to undefined function mysql_connect() in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Irritable bowel syndrome.php:92 Stack trace: #0 {main} thrown in C:\Inetpub\vhosts\kidney.de\httpdocs\bdom\Irritable bowel syndrome.php on line 92